Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Revamping AstraZeneca, Soriot Calls For Focus And Speedier Innovation

Executive Summary

AstraZeneca will accelerate development of several mid-stage assets into Phase III and turn aggressively to business development under CEO Pascal Soriot’s strategy to transform the company, even as it shores up its P&L with more job cuts.


Related Content

Few Q1 Bright Spots For AstraZeneca Puts Pressure On The Pipeline
AstraZeneca, Firing On All Cylinders, Sets Aggressive R&D Goals
End Of An Era? AstraZeneca Closes India Research Site Focused On Tropical Diseases
AZ Is Top Deal-Maker: Neurodegenerative Disease Deals, 2010 – Q1 2013
AstraZeneca’s R&D Restructuring Follows Hot Spot Trend
AstraZeneca Faces Uphill Battle In Talking U.S. Docs Into Using Brilinta
AstraZeneca Deploys High-Sensitivity Troponin Test As Brilinta Biomarker
AZ Taps Outsider Soriot As CEO, While Roche Anoints 25-Year Veteran O'Day To Head Pharma Division
With Bristol/AstraZeneca In Driver’s Seat, GLP-1 Race Takes A Turn
Brennan’s Abrupt Departure Has Some Viewing AstraZeneca As A Buyout Target


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts